CA2801835A1 - Crystalline forms of thalidomide and processes for their preparation - Google Patents

Crystalline forms of thalidomide and processes for their preparation Download PDF

Info

Publication number
CA2801835A1
CA2801835A1 CA2801835A CA2801835A CA2801835A1 CA 2801835 A1 CA2801835 A1 CA 2801835A1 CA 2801835 A CA2801835 A CA 2801835A CA 2801835 A CA2801835 A CA 2801835A CA 2801835 A1 CA2801835 A1 CA 2801835A1
Authority
CA
Canada
Prior art keywords
thalidomide
equal
crystalline
anhydrous
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2801835A
Other languages
English (en)
French (fr)
Inventor
Vinayak Govind Gore
Vinay Kumar Shukla
Madhukar Patil
Sandeep Mekde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CA2801835A1 publication Critical patent/CA2801835A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2801835A 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation Abandoned CA2801835A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1758MU2010 2010-06-09
IN1758/MUM/2010 2010-06-09
PCT/GB2011/051078 WO2011154739A1 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Publications (1)

Publication Number Publication Date
CA2801835A1 true CA2801835A1 (en) 2012-12-15

Family

ID=44384914

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2801835A Abandoned CA2801835A1 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Country Status (8)

Country Link
US (2) US20130143923A1 (enExample)
EP (1) EP2580205A1 (enExample)
JP (1) JP2013528206A (enExample)
CN (1) CN103068812A (enExample)
AU (1) AU2011263493B2 (enExample)
CA (1) CA2801835A1 (enExample)
NZ (1) NZ604011A (enExample)
WO (1) WO2011154739A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924432A (zh) * 2012-11-09 2013-02-13 常州制药厂有限公司 一种高纯度沙利度胺的制备方法
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
BR112015031291A2 (pt) * 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de arilalquil sulfóxido como acaricidas e inseticidas
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
KR20250127179A (ko) * 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
CN104710411B (zh) * 2015-03-13 2017-04-26 安润医药科技（苏州）有限公司 阿伐那非的合成方法
CN110498788B (zh) * 2018-05-16 2021-09-17 欣凯医药化工中间体（上海）有限公司 一种高纯度沙利度胺α晶型的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
CN1164586C (zh) * 2002-10-28 2004-09-01 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide
WO2009083724A1 (en) 2007-12-27 2009-07-09 Cipla Limited Processes for the preparation of thalidomide
CN102260241A (zh) * 2010-05-26 2011-11-30 重庆医药工业研究院有限责任公司 一种沙利度胺α晶型的工业化制备方法

Also Published As

Publication number Publication date
US20150218126A1 (en) 2015-08-06
NZ604011A (en) 2015-04-24
EP2580205A1 (en) 2013-04-17
AU2011263493A1 (en) 2013-01-10
AU2011263493A8 (en) 2013-02-21
JP2013528206A (ja) 2013-07-08
CN103068812A (zh) 2013-04-24
US20130143923A1 (en) 2013-06-06
AU2011263493B2 (en) 2015-08-06
WO2011154739A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
US20150218126A1 (en) Crystalline forms of thalidomide and processes for their preparation
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
US20110263649A1 (en) Crystalline form of lenalidomide and a process for its preparation
EP3887374A2 (en) Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
JP2009537603A (ja) ５−アミノ−３−（２’，３’−ジ−Ｏ−アセチル−ベータ−Ｄ−リボフラノシル）−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンのマレイン酸塩のＡ型及びＢ型結晶形
JP2009514988A (ja) イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
CA2703230A1 (en) Novel crystalline forms
US20080015197A1 (en) Process for the preparatrion of zopiclone
CN101772491A (zh) 基本不含有二聚体杂质的瑞格列奈
CA2644819A1 (en) Process for preparing memantine hydrochloride substantially free of impurities
DK2532651T3 (en) Synthesis process and the crystal form of 4- {3- [cis-hexahydrocyclopenta [c] pyrrole-2 (1 H) -yl] propoxy} benzamide hydrochloride and the free base thereof, and the pharmaceutical compositions containing them
EP2009008A1 (en) Imatinib base, and imatinib mesylate and processes for preparation thereof
JP2004520446A (ja) ロサルタンカリウムの結晶化方法
IL197962A (en) Crystalline form of –3– (1 h– indole – 3 – yl) –4– [2– (4 – methyl – piperazine – 1 – yl) –quinazoline – 4 – yl] –pyrol – 2,5 – deion acetate, preparation A medical containing it, a process for its preparation and its use in the preparation of pharmacological material
WO2014030173A2 (en) An improved process for the preparation of atazanavir bisulfate
JP2006511614A (ja) ナテグリニドの多形性形状
EP2765131B1 (en) Process for the production of Moxonidine
WO2023222946A1 (en) Process for the preparation of cabozantinib
KR101489062B1 (ko) 고순도의 올란자핀 및 이의 결정형 ii의 제조방법
CN119613386A (zh) 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
WO2008152514A2 (en) Process for the preparation of alfuzosin and salts thereof
HK1223928B (en) Novel crystalline arylalkylamine compound and method for producing same

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190709

FZDE Discontinued

Effective date: 20190709